ArticleMicrobiology spectrum2025
Reliability of CMV-IgG kinetics in the diagnosis of CMV primary infection: sensitivity, specificity, and clinical implications.
Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development and performance evaluation of a recombinant antigen - based ELISA and immunochromatography test for HCMV IgG detection.BMC infectious diseases · 2026Article
- Consistent performance of cytomegalovirus IgG assays across platforms contrasts with marked IgM variability, supporting IgG avidity-based infection classification in a high-prevalence population.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diagnosis of cytomegalovirus (CMV) primary infection (PI) during pregnancy relies on serology (CMV-IgG, IgM, and IgG avidity). However, as for toxoplasmosis, subsequent serology testing 3-5 weeks later is often performed to confirm the diagnosis. In this study, we aimed to show that testing CMV-IgG with different assays may lead to misinterpretation of CMV-IgG kinetics and to determine the sensitivity and specificity of CMV-IgG stability and significant increase to exclude or confirm recent CMV PI. We conducted a retrospective study on (i) a CMV-IgG external quality control program (2015-2022) and (ii) on CMV serology results obtained in our virology laboratory (2013-2023) in pregnant women with positive CMV-IgM and a subsequent serum sample collected 3-5 weeks later. Analysis of 21 CMV-IgG external quality control serum samples highlighted significant differences in CMV-IgG values, with variations up to a factor of 185 between different immunoassays for the same positive sample. In 434 pregnant women, the sensitivity of a significant CMV-IgG increase to predict recent PI was 32.9% (95% CI = 26.5-39.2), while CMV-IgG stability specificity to exclude PI <3 months was 32.9% (95% CI = 26.5-39.2). Our observations highlight the discrepancies in CMV-IgG values with different assays and the major importance of CMV-IgG avidity in the diagnosis of recent CMV PI in case of positive CMV-IgM. We also demonstrate that retesting IgG on a sample collected 3-5 weeks later is not helpful and can be confusing.IMPORTANCEThis article is the first to address cytomegalovirus (CMV)-IgG kinetics and their reliability in the serological diagnosis of CMV. In our experience, many clinical virologists and laboratory practitioners still rely on kinetics for diagnosis. However, our study clearly demonstrates that this approach is misleading and that avidity testing should always be performed. Additionally, we conducted a robust study highlighting discrepancies between CMV serology techniques, emphasizing the importance for practitioners, particularly gynecologists, to avoid monitoring serology results using different testing methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.